Eisai Co., Ltd.

FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review [Press Release]
PRNewswire | 1 minute ago
...of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus...S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health...in Woodcliff Lake, New Jersey, Eisai Inc. has several R&D facilities...

Quintiles Announces Strategic Alliance to Advance Eisai s Oncology Pipeline [Press Release]
Business Wire | 25 days 10 hours 55 minutes ago
Quintiles today announced a strategic alliance with leading global pharmaceutical company Eisai Co., Ltd. (Tokyo, Japan) to develop six potential oncology products in Eisai’s R&D pipeline. Under the terms of the agreement, Quintiles’ oncology experts will conduct Phase II proof-of-concept studies for 11 solid tumor indications. A key goal of the alliance is to determine the efficacy of the products in the shortest possible time in order to bring therapies to market faster for the benefit of c...

LUSEDRA(TM) (fospropofol disodium) Injection CIV for Monitored Anesthesia Care (MAC) Sedation Now Available [Press Release]
PRNewswire | 8 days 4 hours 23 minutes ago
WOODCLIFF LAKE, N.J., Nov. 16 /PRNewswire/ -- Eisai Inc. today announced that LUSEDRA(TM) (fospropofol disodium) Injection is now available for use by persons trained in the administration of general anesthesia. LUSEDRA, an aqueous solution, is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures. The U.S. Food and Drug Administration (FDA) approved LUSEDRA in December 2008. LUSEDRA is d...

Eisai Launches New Educational Program for Caregivers of Patients With Rare Form of Epilepsy [Press Release]
MarketWire | 14 days 5 hours 23 minutes ago
WOODCLIFF LAKE, NJ -- (Marketwire) -- 11/10/09 -- Eisai Inc. introduced a new educational program today to help parents and caregivers of patients with Lennox-Gastaut syndrome (LGS), a rare form of epilepsy in which patients have frequent seizures of multiple types. The program is centered on the new Web resource,

Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival [Press Release]
PRNewswire | 25 days 7 hours 53 minutes ago
WOODCLIFF LAKE, N.J., Oct. 30 /PRNewswire/ -- Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

Eisai Inc. and the Alzheimer's Association Honor Community Pharmacist for Outstanding Service to Individuals with Alzheimer's Disease [Press Release]
PRNewswire | 26 days 5 hours 23 minutes ago
...of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus...S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health...in Woodcliff Lake, New Jersey, Eisai Inc. has several R&D facilities...

Eisai Announces Agreement with Pfizer on Strategic Alliance for Alzheimer's Disease Treatment Aricept(R) [Press Release]
PRNewswire | 60 days 20 hours 51 minutes ago
WOODCLIFF LAKE, N.J., Sept. 24 /PRNewswire/ -- Eisai Co., Ltd. announced that it has reached a comprehensive agreement with Pfizer Inc. (Headquarters: New York, CEO and Chairman of the Board: Jeffrey Kindler, "Pfizer") regarding the strategic alliance for the Alzheimer's Disease treatment, Aricept(R) (donepezil hydrochloride). Eisai and Pfizer have been in discussions to resolve their dispute concerning the strategic alliance and development agreement which was signed in October 1994.

Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects [Press Release]
PRNewswire | 61 days 12 hours 21 minutes ago
BERLIN, Sept. 24 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).

Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody [Press Release]
PRNewswire | 27 days 6 hours 53 minutes ago
...of approximately $3.7 billion. Eisai Inc.'s areas of commercial focus...S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health...in Woodcliff Lake, New Jersey, Eisai Inc. has several R&D facilities...

Biocompatibles International plc - Interim Management Statement [Press Release]
PRNewswire | 20 days 11 hours 23 minutes ago
4 November 2009 BIOCOMPATIBLES INTERNATIONAL PLC ("Biocompatibles" or the "Company") Interim Management Statement

Morphotek(R), Inc. Awarded Funding to Develop Therapeutic Antibodies Against Potential Biowarfare Toxins [Press Release]
PRNewswire | 62 days 11 hours 50 minutes ago
...please visit www.morphotek.com Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of...These operating companies include: Eisai Research Institute of Boston, Inc...

SuperGen Reports 2009 Third Quarter Financial Results [Press Release]
Business Wire | 29 days 4 hours 23 minutes ago
SuperGen, Inc. (NASDAQ:SUPG) today reported financial results for the third quarter and nine months ended September 30, 2009.